Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Paclitaxel 4Cyclophosphamide 4exemestane 3Taxes 3Tamoxifen 3Letrozole 3Doxorubicin 3Anastrozole 3Trastuzumab 2Leuprolide 2Immunotherapy 2Goserelin 2Carboplatin 2trastuzumab biosimilar HLX02 1ribociclib 1pegfilgrastim 1elacestrant 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1abemaciclib 1Vitamins 1Standard of Care 1Radiosurgery 1Psychiatric Rehabilitation 1Practice Guidelines as Topic 1PF-05280014 1Ontruzant 1Omeprazole 1Ogivri 1Neoadjuvant Therapy 1Methods 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms, Male × Immunoenzyme Techniques × 1 year × Clear all
NCT00897702 2026-01-28

Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer

Memorial Sloan Kettering Cancer Center

Completed
269 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡